Market Herald logo

Subscribe

Be the first with the news that moves the market
  • NeuroScientific Biopharmaceuticals (NSB) reports “positive” preliminary results from an animal study for multiple sclerosis
  • The study evaluated NSB’s lead drug candidate, EmtinB, across four dose groups in a mouse model, with the drug administered daily for a period of 30 days
  • The results displayed a reduction in the severity of the disease, from the onset of symptoms and through to the peak, when compared to untreated controls
  • Based on the preliminary results, NeuroScientific says it will progress EmtinB into a larger study, and expects to report a full set of in the second half of 2022
  • NeuroScientific Biopharmaceuticals last traded at 17.5 cents on June 14

NeuroScientific Biopharmaceuticals (NSB) has reported “positive” preliminary results for its EmtinB treatment following an animal study for multiple sclerosis.

The clinical-stage drug development company released the results from a “gold standard” animal model trial of multiple sclerosis (MS), which was undertaken by a contract research partner in Canada.

The study evaluated NSB’s lead drug candidate, EmtinB, across four dose groups in a mouse model, with the drug administered daily for a period of 30 days, following the onset of initial symptoms in the mice.

The results showed mice treated with ten milligrams per mouse kilogram (mg/kg) and 20mg/kg doses of EmtinB consistently achieved lower clinical scores. The company explained this indicates a reduction in the severity of the disease, from the onset of symptoms and through to the peak of the disease, when compared to untreated controls.

The treatment was also shown to increase myelin in the models, which is important for the efficient function of nerve cells. The destruction of myelin is thought to contribute to the onset of neurological dysfunction which is associated with MS.

NeuroScientific’s Managing Director and CEO Matt Liddelow said the preliminary results from this are highly encouraging for the development of EmtinB as a treatment for MS.

“In comparison to currently marketed MS therapeutics, EmtinB has the potential to be a disease-modifying treatment option for MS patients with a much more tolerable side-effect profile,” Matt Liddelow said.

Based on the preliminary results, NeuroScientific said it will progress EmtinB into a larger study, and expects to report a full set of results midway through the second half of 2022.

NeuroScientific Biopharmaceuticals last traded at 17.5 cents on June 14.

NSB by the numbers
More From The Market Herald
Cavalier Resources (ASX:CVR) - Executive Technical Director, Daniel Tuffin

" Cavalier Resources (ASX:CVR) begins PFS at Crawford

Cavalier Resources (ASX:CVR) has begun a pre-feasibility study (PFS) at the Crawford Gold Project within the…
Ten Sixty Four (ASX:X64) - Outgoing Managing Director, Paul Ryan Welker

" Ten Sixty Four (ASX:X64) terminates services agreement of former MD, Paul Ryan Welker

Ten Sixty Four (ASX:X64) has terminated the executive services agreement of former Managing Director Paul Ryan…

" M3 Mining (ASX:M3M) identifies drill targets at Edjudina

M3 Mining (ASX:M3M) has identified prospective gold-in-soil anomalies at the Edjudina gold project 150 kilometres northeast…

" Good Drinks Australia (ASX:GDA) commences the sale of Molson Coors and Magners

Good Drinks Australia (ASX:GDA) begins to sell the Miller Chill, Miller Genuine Draught, Coors, Molson Canadian…